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CASE PRESENTATION
A 58-year-old man was referred to the medical oncol-
ogy department of the Beth Israel Deaconess Medical
Center in Boston 2 years ago by his primary care physi-
cian because of newly documented renal and lung masses.
He had presented to his primary care physician a few
weeks earlier for evaluation of decreased libido. Exami-
nation revealed a right-sided varicocele. Workup for the
varicocele included an abdominal computerized tomog-
raphy (CT) scan, which revealed bilateral complex re-
nal masses, an 8 cm mass in the mid-portion of the right
kidney, and a 2.5 cm mass involving the upper pole of
the left kidney. Chest CT scan showed multiple bilateral
pulmonary nodules, the largest being 1 cm in diameter.
His past medical history was significant for hypertension
and allergic rhinitis. He had no significant history of car-
diopulmonary disease. His medicines included lisinopril
and nasal steroids. There was no family history of renal
cancer. He had a 20 pack-year history of smoking, but he
had not smoked for more than 10 years.
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Physical examination in the oncologist’s office revealed
a healthy appearing middle-aged man. His weight was
219.7 pounds. The blood pressure was 160/100 mm Hg.
His Eastern Cooperative Oncology Group (ECOG) Per-
formance Status was zero. Aside from a right-sided
varicocele, the examination was otherwise unremarkable.
Specifically, there was no palpable abdominal mass or
organomegaly.
Magnetic resonance imaging (MRI) of the abdomen
with reconstruction images confirmed the presence of
bilateral renal masses and showed evidence of tumor
thrombosis involving the right renal vein extending to
the junction with the inferior vena cava. No retroperi-
toneal adenopathy was identified. A bone scan and head
CT disclosed no evidence of metastases. The hemoglobin
was 13.7 g/dL, and the calcium and lactate dehydroge-
nase (LDH) levels were normal. An electrocardiogram,
pulmonary function test, and an exercise stress test were
unremarkable.
The patient was referred to a urologist, who performed
a right cytoreductive “debulking” nephrectomy. Pathol-
ogy showed clear cell renal cell carcinoma (RCC) with
alveolar, but no papillary or granular, features. Surgery
was uncomplicated and the patient had a quick recovery.
Upon recovery, he received high-dose interleukin-2 (IL-
2) therapy according to the standard regimen: 600,000
IU/kg every 8 hours on days 1 to 5 and 15 to 19. IL-2
therapy was associated with several typical side effects,
including transient hypotension, weight gain, renal insuf-
ficiency, bilirubinemia, and pruritus. Treatment produced
complete regression of most of the pulmonary nodules;
however, a residual 7 mm right pulmonary nodule and
the left renal mass persisted. An additional cycle of high-
dose IL-2 three months later failed to produce additional
tumor regression.
The patient was observed for several months, dur-
ing which time the lung and renal lesions persisted. Six
months after initiating IL-2, he was referred for video-
assisted thoracoscopic resection of the lung lesion. Resid-
ual renal cancer was detected in the pathology specimen.
The left renal mass was treated with radiofrequency ab-
lation. A followup CT scan 2 months later demonstrated
disease progression with multiple new lung nodules. Var-
ious experimental options were considered, and he was
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Fig. 1. Various histologic patterns, frequencies and characteristic genetic mutations seen in renal cancer. Abbreviations are: VHL, von Hippel-
Lindau disease; FH, fumarate hydratase; BHD, Birt-Hogg-Dube´ syndrome. (Adapted with permission from Linehan WM et al, Clin Cancer Res
10:62825–62895, 2004.)
eventually enrolled in a research protocol involving so-
rafenib (BAY 43-9006), an orally administered raf kinase
inhibitor. Therapy was associated with fatigue, hand rash,
and elevated blood pressure. After 12 weeks of treatment,
restaging CT scans showed a 25% regression in tumor
volume. His therapy was continued, but disease progres-
sion in bone was documented 6 months after initiation of
treatment. The protocol therapy was halted.
DISCUSSION
DR. MICHAEL B. ATKINS (Professor of Medicine,
Harvard Medical School; Deputy Chief, Division of
Hematology/Oncology, Beth Israel Deaconess Medical
Center; and Leader, Renal Cancer Program, Dana Farber/
Harvard Cancer Center; Boston, Massachusetts, USA):
This patient depicts a fairly typical presentation and
course for advanced RCC. His history highlights sev-
eral issues related to the epidemiology, presentation, and
treatment of renal cancer. Treatment issues raised by his
illness include (1) the role of cytoreductive nephrectomy
in patients presenting with stage IV disease, (2) the role
of cytokine-based immunotherapy for stage IV renal can-
cer, (3) prognostic and predictive factors, (4) the role
of salvage surgery in patients with partial response to
cytokine-based therapy, (5) the emerging role of molec-
ularly targeted and antiangiogenic therapy, and (6) the
persistent need for improved therapy. All these issues
will be discussed in the context of this case.
Malignant tumors of the kidney make up 3% of new
cancer diagnoses and deaths each year in the United
States. Approximately 32,000 cases and 12,000 deaths
were anticipated in 2004 [1]. Renal cell cancer, which rep-
resents the vast majority of kidney tumors, occurs more
often in men than in women. The mean age at diagno-
sis is around 60 years. The incidence rates for RCC have
been rising each year in the United States since the 1970s,
with recent increases being more rapid among blacks than
whites. The worldwide incidence is highest in Scandinavia
and other parts of northern Europe and in North Amer-
ica. The lowest rates are reported in India, China, Japan,
and areas of Central and South America.
Most of the information on risk factors for RCC has
come from case-control studies, with the largest studies
comprising 1732 cases and 2309 controls [2–4]. Cigarette
smoking is an established causal risk factor for RCC,
with the relative risk among smokers from case-control
and cohort studies ranging from 1.2 to 2.3 [2]. Approx-
imately 20% to 30% of RCCs in men and 10% to 20%
in women can be accounted for by cigarette smoking.
Obesity, particularly in women, has been associated with
RCC [3], as has hypertension. Some studies have sug-
gested that the use of certain drugs, such as thiazide
diuretics, and occupational exposure to toxins, such as
polycyclic aromatic hydrocarbons (in coke oven work-
ers), trichloroethylene, and perchloroethylene (in dry
cleaning employees), are associated with an increased
risk of RCC. However, no firm data have established
a link between these drugs/toxins and RCC. Acquired
cystic disease of the kidney, occurring in 80% to 95%
of patients undergoing hemodialysis and 30% to 45%
of those undergoing peritoneal dialysis, predisposes to
RCC. These patients have a 5% to 30% likelihood of
developing RCC, typically papillary in type, and approx-
imately 15% of those who do develop RCC will present
with metastatic disease.
In 1997, a new classification of renal epithelial tumors
was adopted that established distinct subtypes based on
morphology, genetic features, and cell of origin [5, 6]
(Fig. 1). Conventional (clear cell) RCC comprises 65%
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to 75% of renal epithelial tumors and is derived from
proximal convoluted tubule cells. Most cases are spo-
radic, unilateral, and unifocal. These tumors tend to show
a mixture of cytoplasmic features, with clear or granu-
lar eosinophilic cytoplasm. Approximately 50% of cases
exhibit either a solid or alveolar growth pattern exclu-
sively, whereas the remaining cases contain a mixture of
growth patterns, including cystic, pseudopapillary, tubu-
lar, and sarcomatoid. Papillary RCC comprises 10% to
15% of RCCs. Papillary tumors derive from cells of the
distal convoluted tubule and are more likely to be bilat-
eral and multifocal. More recently, papillary tumors have
been subdivided into papillary type 1 and type 2. The clas-
sic papillary pattern is characterized by discrete papillary
fronds lined by neoplastic cells and containing a central
fibrovascular core. Chromophobe RCC comprises 5%
to 10% of renal epithelial tumors, is derived from in-
tercalated cells, and tends to be an indolent tumor that
grows quite large but usually remains confined to the kid-
ney. The majority of chromophobe tumors demonstrate
variable granular and diffuse blue cytoplasmic staining
with Hale’s colloidal iron. Collecting duct carcinoma,
also known as Bellini’s duct carcinoma, accounts for less
than 1% of renal epithelial tumors. The cell of origin is
from the collecting ducts of the renal medulla. Collecting
duct cancers contain tumor cells with high-grade cytology
that are arranged in nests and tubules and are associated
with stromal desmoplasia. Tumor cells can exhibit a hob-
nail morphology, contain mucin, and demonstrate pos-
itive staining with the lectin Ulex europaeus agglutinin.
These rare cancers tend to present in younger patients
and are aggressive; more than 50% of patients present
with metastatic disease. Medullary carcinoma, like col-
lecting duct carcinoma, is a rare, aggressive tumor derived
from the distal portions of the collecting ducts. It occurs
predominantly in African American patients with sickle
cell trait. Oncocytomas comprise 5% of all primary renal
neoplasms, are derived from intercalated cells, and are
benign tumors. The dominant cell type in this tumor has
abundant, densely eosinophilic cytoplasm and a round
nucleus with a prominent nucleolus, and is arranged in
nests and tubules.
Renal cancer subtypes are increasingly distinguished
by unique genetic abnormalities and associated gene
expression patterns [7, 8]. The genetic abnormali-
ties were first identified through studies of familial
cancer syndromes. Von Hippel-Lindau disease (VHL)
is an autosomal-dominant, multi-organ, familial can-
cer syndrome characterized by the development of
cerebellar/spinal hemangioblastomas, retinal angiomas,
pheochromocytomas, and renal cysts/tumors. Renal cell
cancer develops in 40% to 60% of VHL patients, and is
exclusively of the clear cell histologic type. These tumors
tend to be multicentric and bilateral, and they occur at an
earlier age. The human VHL gene maps to chromosome
sub-band 3p25 [9]. Germline mutations of the VHL gene
occur in 100% of patients presenting with the VHL clin-
ical phenotype, and genetic analysis of VHL-associated
clear cell renal cell cancer shows loss of heterozygosity
(LOH) at the VHL locus due to deletion of the wild-type
allele [10]. In sporadic, clear cell RCC, LOH at the VHL
locus is present in 75% to 80% of cases, along with ei-
ther simultaneous mutational inactivation or silencing by
methylation of the remaining allele. This finding impli-
cated mutations of the VHL gene in the pathogenesis of
both hereditary and sporadic clear cell cancers.
The VHL gene encodes a tumor suppressor pro-
tein that forms a complex that in the presence of oxy-
gen binds to hypoxia-inducible factor (HIF), targeting
it for proteasomal destruction. In hypoxic conditions,
HIF accumulates and stimulates the synthesis of var-
ious hypoxia-induced proteins, including vascular en-
dothelial growth factor (VEGF), transforming growth
factor-beta 1 (TGF-b1), platelet-derived growth factor-
beta (PDGF-b), erythropoietin, and GLUT-1. In the ab-
sence of VHL, HIF accumulates, even under normoxic
conditions, and HIF-inducible proteins are inappropri-
ately overexpressed and contribute to the malignant phe-
notype of clear cell tumors (Fig. 2).
Hereditary papillary renal carcinoma (HPRC) is a rare
inherited condition that was first reported in 1994 [11].
Affected individuals in HPRC kindreds were found to be
at risk for the development of bilateral, multifocal type-1
papillary RCC. Genetic studies in HPRC kindreds led to
the identification of the c-Met gene on chromosome 7 as
the gene responsible for HPRC [12]. The c-Met recep-
tor belongs to the tyrosine kinase receptor superfamily,
and hepatocyte growth factor/scatter factor (HGF/SF) is
its ligand. That activating point mutations in c-Met have
been found in type-1 papillary RCC suggests a causative
role in disease progression.
More recently, two additional familial syndromes have
been linked to RCC: Birt-Hogg-Dube´ (BHD) and fu-
marate hydratase (FH). A hereditary cancer syndrome,
BHD places affected individuals at risk for the develop-
ment of cutaneous nodules; pulmonary cysts and spon-
taneous pneumothorax; and bilateral, multifocal renal
tumors [13]. Genetic studies in BHD kindreds led to the
localization and subsequent identification of the BHD
gene [7, 14]. On the other hand, FH has been identified
as the gene for hereditary leiomyomatosis RCC. Both
BHD and FH appear to function as tumor-suppressor
genes, and their damage appears to be associated with
the development of chromophobe and type-2 papillary
RCC, respectively [7, 15].
Clinical presentation
Renal cell cancer often remains clinically occult un-
til the primary tumor has grown quite large or until
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Fig. 2. Pathophysiology of von Hippel-Lindau (VHL) mutations in clear cell renal cell carcinoma (RCC). Mutations disrupt the VHL complex
creating a pseudohypoxic condition in which the VHL complex cannot bind to hypoxia-inducible factor (HIF) and targets its destruction in the
proteasome. As a result, HIF accumulates and increases the expression of various HIF-inducible proteins [transforming growth factor-b (TGF-b),
vascular endothelial growth factor (VEGF), and platelet-derived growth factor (PDGF)]. This increase leads to autocrine growth stimulation and
pro-angiogenic effects, which contribute to renal cancer development and progression.
metastases cause constitutional symptoms or pain. As ul-
trasound and CT have been used more frequently to eval-
uate nonspecific abdominal complaints, the incidental
diagnosis of RCC has become more common [16, 17]. At
present, approximately 60% to 70% of patients present
with localized disease, 10% to 15% are diagnosed with re-
gional spread, and 20% to 25% have distant metastases.
Pain, gross hematuria, and palpable mass are the most
common presenting signs and symptoms, and are often an
indication of locally advanced disease. However, only 5%
of patients present with all three (Virchow’s triad). Pa-
tients also can present with new-onset varicocele, lower
extremity edema, or even full-blown Budd-Chiari syn-
drome, which result from tumor thrombus extension into
and/or obstruction of the testicular vein, inferior vena
cava, or hepatic vein, respectively. While varicoceles from
renal cancer are usually left-sided owing to the drainage
of the left testicular vein into the left renal vein, any
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new-onset varicocele in an adult, as in today’s patient,
should prompt the performance of a CT scan to rule out
renal cancer.
The lungs, lymph nodes, liver, bone, and adrenal glands
are the most common sites of metastases, and patients
initially can present with cervical/supraclavicular lym-
phadenopathy, bone pain, or respiratory symptoms due
to hilar/mediastinal adenopathy, pleural effusion, and/or
parenchymal lung metastases. Less commonly, patients
present with subcutaneous metastases or metastases to
unusual sites such as the thyroid gland, sinuses, or other
mucosal surfaces. Although 5% to 10% of patients with
advanced disease develop central nervous system metas-
tases, brain metastases are rare at initial presentation.
Many paraneoplastic syndromes are associated with
RCC, and occur in patients with either localized or
advanced disease [18]. Anemia (often an anemia of
chronic disease) and constitutional symptoms such as
fever, malaise, anorexia, and weight loss are among the
most common findings and are present in 20% to 40%
of patients at the time of diagnosis. Hepatic dysfunc-
tion in the absence of liver metastases (Stauffer syn-
drome), characterized by an elevation of the serum
alkaline phosphatase and/or hepatic transaminases, is
present in 5% to 10% of patients. Polycythemia and
hypertension, due to the production by tumor cells of
erythropoietin and renin, respectively, can be observed
in patients with localized and advanced disease. Hy-
percalcemia, more common in patients with advanced
disease, is often due to the production of parathyroid-
hormone–related protein by tumor cells. Other less
common paraneoplastic syndromes include amyloidosis,
neuromyopathy, and acquired dysfibrinogenemia. Many
of these paraneoplastic syndromes, including anemia, hy-
percalcemia, constitutional symptoms, and abnormalities
of liver function tests, signify more aggressive disease and
typically a worse prognosis.
Treatment
Cytoreductive nephrectomy. The patient under discus-
sion today presented with stage IV disease with his pri-
mary tumor intact. Consequently, the first therapeutic
question that needed to be addressed was the value of
cytoreductive “debulking” nephrectomy. Recent studies
have suggested that the effectiveness of immunotherapy
in patients with metastatic RCC can be enhanced follow-
ing cytoreductive nephrectomy [19, 20]. For example, the
Southwest Oncology Group (SWOG) randomly assigned
246 patients presenting with metastatic disease to receive
interferon-a (IFN-a) (5 mIU/m2 three times weekly) ei-
ther alone or following debulking nephrectomy [19]. Al-
though few responses to IFN-a were observed with ei-
ther treatment arm, the median overall survival was sig-
nificantly longer for patients undergoing cytoreductive
nephrectomy (12.5 versus 8.1 months). Other investiga-
tors have confirmed these results [20, 21]; thus, bulky
primary tumors might facilitate disease progression, pre-
sumably through immune suppression.
Historically, many patients with metastatic RCC
who underwent debulking nephrectomy never received
planned immunotherapy either because of surgical com-
plications or rapid disease progression. Consequently,
patients should be judiciously selected for debulking
nephrectomy prior to receiving systemic immunother-
apy. In studies performed at Tufts-New England Medical
Center, Fallick and colleagues developed and tested the
following criteria for pretherapy debulking nephrectomy
[22]: greater than 75% tumor debulking possible; no cen-
tral nervous system or extensive liver or bone metastases;
adequate pulmonary and cardiac function; ECOG perfor-
mance status of 0 or 1; and biopsy, if performed, showing
clear-cell-type histology. These criteria were applied to
90 patients with metastatic RCC; 28 (30%) were found
to be eligible for surgery; 26% of these 28 (93%) had
debulking nephrectomy and went on to receive planned
IL-2–based immunotherapy; and 10 of these 26 patients
(39%) who received IL-2 following debulking nephrec-
tomy responded to treatment.
This encouraging response rate for IL-2–based therapy
following debulking nephrectomy was confirmed in a re-
cent retrospective analysis of a large phase III Cytokine
Working Group trial comparing high-dose IL-2 to outpa-
tient IL-2 and IFN-a [21]. Of the 40 patients who had a
nephrectomy within 90 days of IL-2 therapy, the response
rate was 22% (9 of 40), median survival was 14 months,
and 4 patients, all of whom received high-dose IL-2, were
progression-free at 3 years. This response rate appeared
to be superior to that reported with IFN-a alone in this
setting and suggested that either high-dose IL-2 or the
combination of IL-2 and IFN-a is more advantageous
than IFN-a alone following cytoreductive surgery.
The patient under discussion presented with a large
right renal mass and small pulmonary metastases. Even
though he also had a small left renal mass, he satisfied
the criteria listed for cytoreductive nephrectomy prior
to systemic immunotherapy. The small left renal mass
was considered too inconsequential to interfere with the
effect of systemic therapy, and if it were persistent and
clinically relevant, it could be dealt with after the effect
of systemic therapy was known.
Cytokine-based immunotherapy. The next therapeutic
issue to be addressed in this patient was the choice of
first-line systemic therapy. Immunotherapy remains the
mainstay of systemic treatment for renal cancer. While a
number of immunotherapeutic approaches have shown
antitumor activity, the most consistent results have been
reported with cytokine-based therapy, particularly with
IFN-a and IL-2. Although the mechanism of action of
these cytokines remains to be fully elucidated, antitumor
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effects in murine models have been linked to the direct
killing of tumor cells by activated T-cells and natural killer
(NK) cells, as well as to anti-angiogenic effects. Given the
limitations of these agents, recent research has focused on
the use of IFN-a in combination with other agents and
in identifying predictive factors that might enable IL-2
therapy to be applied more selectively to patients who
are most likely to benefit.
Interferon-a has undergone extensive clinical evalua-
tion over the past two decades in metastatic RCC. Results
of these investigations are thoroughly described in sev-
eral reviews [23, 24]. Despite the use of a variety of prepa-
rations, doses, and schedules, most studies have shown
modest antitumor activity, with the overall response rate
being approximately 10% to 15%. Responses are often
delayed in onset, with median time to response being
approximately 4 months. Most responses are partial and
short-lived (median response duration, 6 to 7 months).
About 2% of patients have had complete responses; only
an occasional patient has had a response persist in excess
of 1 year after therapy [25]. While no clear dose-response
relationship exists, daily doses in the 5 to 10 MIU range
appear to have the highest therapeutic index. The toxicity
of IFN-a includes flu-like symptoms such as fever, chills,
myalgias, and fatigue, as well as weight loss, altered taste,
depression, anemia, leukopenia, and elevated liver func-
tion tests. Most side effects, especially the flu-like symp-
toms, tend to diminish with time during chronic therapy.
Recent studies have suggested that IFN-a, despite hav-
ing limited antitumor activity, can produce a modest
impact on survival. For example, a phase III trial com-
paring IFN-a2a plus vinblastine chemotherapy to vin-
blastine alone reported a median survival of 67.6 weeks
for the combination arm compared to 37.8 weeks for pa-
tients receiving vinblastine alone (P = 0.0049) [26]. In
another trial that randomized patients with advanced dis-
ease to either IFN-a or medroxyprogesterone, the IFN-a
group had a 28% reduction in risk of death (P = 0.017)
and an improved median survival of 2.5 months [27].
Despite its long track record of modest clinical activ-
ity, IFN-a continues to be actively investigated in pa-
tients with advanced renal cancer. Interferon has an
excellent safety profile, multiple potential mechanisms
of action, outpatient administration schedule, and famil-
iarity to the community oncologist. This set of factors
has prompted its use as the control arm in many coop-
erative group and industry-sponsored phase III trials of
novel agents and its use in combination with other poten-
tially active agents in renal cancer, including IL-2, 13 cis-
retinoic acid, thalidomide, CCI-779, and bevacizumab.
Although the addition of cis-retinoic acid to IFN-a pro-
duced no significant benefit [28], and combinations of
IL-2 and IFN-a have produced mixed results, studies
involving other combinations have only recently been
initiated.
Inpatient high-dose bolus IL-2 received federal Food
and Drug Administration (FDA) approval for the treat-
ment of patients with stage IV RCC in 1992 based on
data on 255 patients who were entered into seven phase
II clinical trials [29, 30]. In these studies, patients received
600,000 to 720,000 IU/kg of recombinant human IL-2
by 15-minute infusion every 8 hours during two 5-day
courses (maximum 14 doses per course) separated by 5
to 9 days of rest. Stable or responding patients received
2 to 5 courses of therapy at 8- to 12-week intervals and
then were observed when all therapy was discontinued.
Objective responses were seen in 37 of the 255 patients
(15%), including 17 complete responses (7%) and 20 par-
tial responses (8%). The median duration of response
was 54 months for all responders, 20 months for partial
responders, and has not yet been calculated for complete
responders. The median survival was 16 months for all
255 patients. Follow-up data on these patients accumu-
lated through June 2002 (median follow-up of more than
10 years) confirm the remarkable durability of these re-
sponses (Fig. 3) [31]. Although some late relapses have
been observed, the response duration curve appears to
have leveled off after the 30-month time point, and 60%
of complete responders remain in remission.
Although the inpatient high-dose bolus IL-2 regimen
produces favorable outcomes in a handful of patients, it
also is associated with significant toxicity and cost and is
not universally available, making it an unsuitable stan-
dard. Low-dose IL-2 regimens (with or without IFN-a)
have produced similar response rates and survival in non-
randomized phase II trials, but responses appeared to
be less durable than those seen with high-dose IL-2 [32–
35]. For example, in a series of phase II trials carried
out sequentially by the Cytokine Working Group, 3-year
progression-free survival was 9%, and median response
duration was 53 months for patients who received high-
dose IL-2 compared to 2% to 3% and 12 months for
lower-dose IL-2 and IFN regimens. Although these trials
involved the same treating physicians, relatively constant
referral patterns, and identical response assessment and
patient eligibility criteria, it was impossible to exclude
selection bias or chance as an explanation for the appar-
ent superiority of the high-dose IL-2 regimen in terms of
response quality.
In an effort to determine the value of outpatient
subcutaneous IL-2/IFN relative to high-dose IL-2, the
Cytokine Working Group performed a prospectively ran-
domized phase III trial in 192 patients [36]. Patients
were randomized to receive either outpatient IL-2 (5
MIU/m2 subcutaneously every 8 hours × 3 doses on day
1, then daily 5 days per week for 4 weeks) and IFN-a2B
(5 MIU/m2 subcutaneously, thrice weekly × 4 weeks) ev-
ery 6 weeks, or high-dose inpatient IL-2 (600,000 IU/kg/
dose intravenously every 8 hours, days 1 to 5 and
15 to 19, maximum 28 doses) every 12 weeks. Tumor
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Fig. 3. Response durations for patients who
received high-dose interleukin-2 (IL-2) in the
original 255 patient cohort reported to the fed-
eral Food and Drug Administration (FDA),
updated through 2002. Abbreviations are:
CR, complete response; PR, partial response.
(Adapted with permission from [31].
responses were assessed at weeks 6 and 12, then every
12 weeks. Responding patients getting IL-2/IFN received
up to 6 cycles at 6-week intervals; responding patients
on high-dose IL-2 received up to 3 cycles at 12-week
intervals.
In the study, 96 patients were assigned to each treat-
ment arm. Patients were stratified for bone or liver metas-
tases, whether the primary tumor was intact or removed,
and performance status 0 or 1. The response rate for high-
dose IL-2 was 23% (22/96) versus 9% (9/96) for IL-2/IFN
(P = 0.018). Eight patients achieved a complete response
on high-dose IL-2 versus 3 on low-dose IL-2/IFN. The
median response durations were 14 months for high-dose
IL-2 (range, 3 to 50+ months) and 7 months for IL-2/IFN
(range, 4 to 38+ months) (P = 0.18). Median overall sur-
vivals were 17 and 13 months (P = 0.12), favoring high-
dose IL-2. Median progression-free survival was 3 months
for both treatments. The primary end point of the study
was 3-year progression-free survival. Nine patients taking
high-dose IL-2 were progression-free at 3 years versus 2
on IL-2/IFN (P = 0.06).
Responses to high-dose IL-2 were seen with equal fre-
quency across the stratification criteria, whereas low-dose
IL-2/IFN appeared to produce more responses in patients
without liver and/or bone metastases and in those who
had undergone prior nephrectomy to remove the pri-
mary tumor. For patients with bone or liver metastases
(P = 0.002) or patients whose primary tumor was not re-
sected (P = 0.54), survival was superior with high-dose
IL-2 compared to IL-2/IFN. Quality of life was assessed
using the EORTC QLQ-C30 questionnaire at seven time
points during therapy; six functional and nine symptom
scales were evaluated. Compared to IL-2/IFN, patients
receiving high-dose IL-2 noted diminished quality of life
on some symptom scales early in therapy, but they experi-
enced overall improved function and fewer symptoms—
an overall better quality of life—during the course of
treatment [37]. Similar response, response duration, and
quality-of-life data were observed by Yang et al in a phase
III trial comparing high-dose IL-2 to either intermediate-
dose intravenous IL-2 or subcutaneous IL-2 given on an
outpatient basis [38].
Taken in aggregate, these data suggest that relative to
patients receiving low-dose IL-2/IFN as outpatients, high-
dose IL-2 produces overall better tumor response and a
borderline significant difference in number of patients
progression-free at 3 years. The benefit of high-dose IL-2
is particularly evident in patients with primary tumors not
resected and in those with liver or bone metastases. Con-
sequently, high-dose IL-2 should remain the preferred
therapy for appropriately selected patients with access to
such therapy. Although there remains much room for re-
finement of appropriate selection criteria for high-dose
IL-2, this therapy appeared to represent the best option
for the patient in question.
Predictors of benefit. Considerable data are now avail-
able that can help predict the outcome for patients with
advanced renal cancer who receive cytokine-based im-
munotherapy. Factors that have been variably associ-
ated with response include performance status, number
of organs with metastases (one versus two or more),
absence of bone metastases, prior nephrectomy, degree
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of treatment-related thrombocytopenia, absence of prior
IFN therapy, thyroid dysfunction, rebound lymphocyto-
sis, erythropoietin production, and post-treatment eleva-
tions of blood tumor necrosis factor a (TNFa) and IL-1
levels [31].
Motzer and colleagues have shown in patients receiv-
ing IFN that poor survival is associated with low Karnof-
sky performance status, high serum lactate dehydroge-
nase, low hemoglobin, high “corrected” serum calcium,
and time from diagnosis of RCC to start of therapy of
less than 1 year [39]. In a cohort of 453 patients who
received IFN as initial therapy, the median survival for
the favorable (no risk factors), intermediate (one or two
risk factors), and poor (three or more risk factors) risk
groups were 30, 14, and 5 months, respectively. Figlin et
al identified prior nephrectomy and time from nephrec-
tomy to relapse as important predictors of survival in
patients receiving IL-2–based therapy [40]. In their se-
ries, patients who received systemic immunotherapy for
metastatic disease more than 6 months after nephrec-
tomy had the best median survival and had a 3-year sur-
vival rate of 46%. A recent multivariate analysis by the
same group of investigators that was confined to patients
who received IL-2 after nephrectomy revealed survival
to be inversely associated with lymph node involvement,
constitutional symptoms, sarcomatoid histology, metas-
tases involving sites other than bone or lung or multi-
ple sites, and a thyroid-stimulating hormone (TSH) level
greater than 2.0 mIU/L [41]. They proposed a scoring al-
gorithm based on these features in which survival at 1
year was predicted to vary from 10% to 92%. Recent
data from the Cytokine Working Group phase III trial
suggested that disease site factors such as primary tumor
in place, or hepatic or bone metastases, are more predic-
tive of a poor response to low-dose IL-2 and IFN regi-
mens than to high-dose IL-2 [21, 31, 36]. Furthermore,
this study suggested that the greatest benefit from high-
dose IL-2 relative to lower dose regimens might be seen
in patients with primary tumors in place and/or liver and
bone metastases. These data call into question some of the
prior studies and suggest that additional predictors of re-
sponse and survival in patients receiving cytokine-based
immunotherapy are necessary. Taking all these data into
consideration, one would estimate today’s patient to have
an above-average chance of responding to IL-2–based
therapy.
We recently performed a blinded, large-scale reanal-
ysis of pathology specimens from patients who received
IL-2–based therapy as part of Cytokine Working Group
trials [42]. We determined that response to IL-2 was sig-
nificantly associated with clear cell histology with alve-
olar features and the absence of papillary or significant
granular features. Patients with these features in their kid-
ney tumor specimens had a 25% response rate (29/115)
compared to a 4% response rate (2/50) for patients with
papillary features >50% granular features or no alveo-
lar features. The results in the kidney tumor specimens
were confirmed in a separate analysis of metastatic lesions
(patients with primary tumors intact). In this setting, re-
sponses were limited to patients with clear cell tumors
with the favorable histologic patterns described in the
primary tumor specimens.
Carbonic anhydrase IX (CAIX) was recently identi-
fied as a molecular marker that can potentially predict
response to IL-2. CAIX expression is mediated by the
HIF-1 alpha transcriptional complex and induced in
many tumor types, but it is absent in most normal tissues.
Bui et al used a monoclonal antibody designed to de-
tect CAIX expression to perform an immunohistochemi-
cal analysis of paraffin-embedded RCC specimens. They
showed that greater than 90% of RCCs express CAIX
and that its expression decreases with advancing stage
[43]. High CAIX expression in primary tumors, seen in
79% of patients, was associated with improved overall
survival in patients with advanced disease and possibly
response to IL-2–based therapy. In addition, all long-term
responders to IL-2–based treatment had high CAIX ex-
pression.
Building on this work, we performed a nested case
control study within the larger cohort of patients whose
pathology was analyzed [44]. CAIX expression levels
were correlated with response to IL-2, pathologic risk
categorization, and survival. Of 27 responding patients,
21 (78%) had high CAIX expression compared to 20 of
39 (51%) nonresponders (odds ratio = 3.3, P = 0.04). Me-
dian survivals were threefold longer in patients with high
CAIX-expressing tumors (P = 0.04), and survival longer
than 5 years was only seen in the group with high CAIX
expression. High CAIX staining was associated with bet-
ter pathology features but remained an independent pre-
dictor of response. For example, in patients within the
intermediate pathology group, nine of nine responders
had high CAIX expression versus 11 of 22 nonrespon-
ders. A two-compartment model was proposed in which
one group of patients with either good pathology or inter-
mediate pathology and high CAIX expression contained
26 of 27 patients (96%) who exhibited a response to IL-2
(odds ratio = 30; P < 0.01). Significant survival benefit
was also seen for this group (P < 0.01). While this model
requires prospective validation, it highlights the potential
for using pathologic and molecular features of the tumor
to identify patients who will receive optimal benefit from
IL-2 therapy. Additional studies to explain these prelim-
inary observations and correlate results with previously
described clinical features are necessary. In addition, gene
expression profiling of tumor specimens should identify
new proteins or patterns of gene expression that might
be associated with IL-2 responsiveness, perhaps further
narrowing the application of IL-2 therapy to those who
will benefit the most.
Role of salvage surgery. In the initial cohort of 255
patients treated with high-dose IL-2, six individuals
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underwent surgical resection of residual disease while still
in response. Of these six individuals, four remain alive and
disease-free a minimum of 65 months following surgery
[31]. These patients either showed no tumor in the re-
section specimen, or more commonly tumor heavily infil-
trated by lymphocytes indicative of an ongoing immune
reaction directed against the cancer. Thus, like patients
achieving a complete response to therapy, many individ-
uals with partial responses resected to “no evidence of
disease” after high-dose IL-2 are unlikely to progress
and actually might be cured. These data supported the
attempted resection of the residual lung metastasis and
the minimally invasive procedure (radiofrequency abla-
tion) for the renal lesion in today’s patient. Unfortunately,
disease progression commenced shortly after these local
procedures were performed.
Molecularly targeted therapies. There is no estab-
lished second-line therapy for patients whose disease
has progressed after cytokine-based therapy. Experience
confirms the futility of reinstitution of IL-2 or switch-
ing to IFN-a in this setting. Other experimental ap-
proaches such as thalidomide, novel cytokines (includ-
ing IL-4, IL-6, and IL-12), vaccine-based therapy, and
cytotoxic chemotherapy have produced only rare tumor
regressions [17]. Fortunately, recent advances in the un-
derstanding of renal cancer biology and the signaling
pathways triggered by the binding of HIF-regulated pro-
teins [VEGF, PDGF, and transforming growth factor-
b (TGF-b)] to their receptors on endothelial, pericyte,
and tumor cells has led to the examination of a vari-
ety of anti-angiogenic and molecularly targeted agents
in patients with renal cancer. These agents include be-
vacizumab, PTK787, SU11248, sorafenib, and CCI-779;
their presumed sites of action are shown in Figures 4
and 5.
VEGF-targeted strategies. Several therapeutic strate-
gies aimed at inhibiting tumor angiogenesis, including
monoclonal antibodies that neutralize circulating VEGF
and inhibitors of signaling through the VEGF receptor,
have been studied in RCC. A double-blind, randomized
phase II study comparing two dose levels of bevacizumab
(an antibody directed against VEGF) versus placebo in
patients previously treated with cytokine therapy showed
significantly improved progression-free survival [45] for
the patients treated with high-dose bevacizumab. Specif-
ically, progression-free survival at 4 months was 60% in
the high-dose group versus 20% in the placebo group.
Of the patients given high-dose bevacizumab (10 mg in-
travenously every 2 weeks), 10% exhibited a partial re-
sponse, and many others had measurable, but less than
50%, disease regression. Crossover was permitted at time
of progression, perhaps confounding any potential over-
all survival benefit. The benefit of bevacizumab in previ-
ously untreated patients is being investigated in a large,
randomized, phase III Cooperative Group study compar-
ing IFN-a with IFN-a and bevacizumab with survival as
the primary end point.
Small molecules that specifically inhibit the VEGF re-
ceptor have been tested in many disease settings includ-
ing in patients with RCC. These targeted therapies block
the adenosine triphosphate (ATP)-binding site of the in-
tracellular portion of the receptor. Many of these agents
block activation of other tyrosine kinases as well [46].
PTK787/ZK222584 is an oral inhibitor of vascular en-
dothelial growth factor receptor (VEGFR)-1, -2, and 3
that has been tested in a phase I study confined to pa-
tients with metastatic RCC. No maximum tolerated dose
was reached in 45 patients treated at five dose levels rang-
ing from 300 to 1500 mg/day [47]. The most commonly re-
ported adverse events were nausea, fatigue, and vomiting.
In 37 patients able to be evaluated, seven had a measur-
able tumor response (one partial and six minor). Another
agent, SU11248, specifically inhibits several tyrosine ki-
nase receptors, platelet-derived growth factor receptor
(PDGFR), KIT, FLT3, and VEGFR. Asthenia, the ma-
jor side effect, was readily reversible when the drug was
held for two weeks of each 6-week cycle. A phase II in-
vestigation of this agent in patients with advanced RCC
produced partial responses in 15 (24%) and stabilized
disease in 29 (46%) of 63 patients [49]. The median re-
sponse duration was more than 6 months. Toxicity gener-
ally was low grade; however, two patients were removed
from the study because of an asymptomatic decline in
left-ventricular ejection fraction of >20%. Confirmatory
trials in the untreated and cytokine-refractory popula-
tions are now underway.
B-raf inhibition. Raf kinase is an important mediator
of the Ras/Raf/MEK pathway. Activating mutations have
been identified in multiple solid tumors including as many
as 70% of patients with melanoma [50]. Although activat-
ing mutations or overexpression of Raf family members
has not been observed in RCC, constitutive activation
of Raf, MEK, and ERK has been observed in approxi-
mately 50% of RCCs [51]. This activation is possibly me-
diated through the CXCR4 pathway. Sorafenib is a po-
tent inhibitor of the wild-type c-raf kinase as well as the
wild-type and V599E mutant b-raf kinases. In addi-
tion, sorafenib inhibits other tyrosine kinases such as
VEGFR2, FLT-3, PDGFR, and FGFR1.
Sorafenib was well-tolerated in clinical trials. Re-
versible skin rash, hand-foot syndrome, diarrhea, and fa-
tigue were the most commonly observed toxicities [52].
In a recent multidisease phase II trial, sorafenib, ad-
ministered 400 mg twice daily, produced tumor regres-
sions (MR and PR) in 25 (40%) of the first 63 patients
with metastatic renal cancer who could be evaluated [53].
At least seven patients had confirmed partial responses.
These encouraging results have prompted a phase III
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Fig. 4. Pathways within the cell that con-
tribute to renal cell progression. Epider-
mal growth factor receptor (EGFR) and
CXCR4 activiation lead to mitogen-activated
protein (MAP) kinase activation. PTEN
methylation leads to mTOR activation and
increased hypoxia-inducible factor (HIF) syn-
thesis, which, in the presence of von Hippel-
Lindau (VHL) mutations, accumulates and
stimulates HIF-mediated protein expression,
closing the autocrine loop. A variety of agents
that inhibit various signaling pathways are
currently under investigation.
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Fig. 5. The pathways within the endothe-
lial cell that contribute to renal cell pro-
gression. Vascular endothelial growth factor
(VEGF) binds to its receptors inducing vascu-
lar growth. Several agents block VEGF either
by binding to it (antibodies), blocking recep-
tor signaling (small molecules) or by blocking
at several steps inside the endothelial cell.
study of sorafenib versus placebo as second-line therapy
in patients with cytokine-refractory, advanced RCC.
CCI-779. Several lines of evidence suggest that in-
hibiting the mTOR pathway is beneficial in the treatment
of renal cell carcinoma. The mTOR pathway is down-
stream of the phosphoinositide 3-kinase and Akt path-
way, which is regulated by the PTEN tumor-suppressor
gene. Although mutations in PTEN have not been de-
tected in RCC, diminished protein expression with in-
creased levels of phospho-AKT have been observed
[54]. Activation of mTOR also can increase HIF-1a
gene expression, which in the setting of VHL mutations
can accentuate HIF accumulation and the expression of
HIF-inducible genes. Thus, the inhibition of the mTOR
pathway in RCC has the potential of inhibiting tumor
progression at several levels [55].
CCI-779 is a rapamycin analogue that also inhibits
mTOR kinase activity and results in G1 cell cycle arrest
[56]. In a randomized phase II study investigating three
different doses of CCI-779 (25 mg, 75 mg, and 250 mg)
[57], an objective response rate of 7% (one complete
response) was observed; 26% of patients had minor re-
sponses. The median time to progression was 5.8 months,
and median overall survival was 15 months. The most
commonly observed toxicities were maculopapular rash,
mucositis, asthenia, and nausea. The most frequent grade
3 or 4 adverse events were hyperglycemia, hyperphos-
phatemia, anemia, and hypertriglyceridemia. When pa-
tients were separated into risk groups as defined by
Motzer et al [39], median survival for patients within
the intermediate and poor risks groups appeared to be
longer for patients receiving CCI-779 than in comparable
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patients who had received IFN-a in the Memorial Sloan
Kettering group despite the fact that the patients in
this trial were receiving CCI-779 as second- or third-line
therapy.
The combination of CCI-779 and IFN was evaluated
in a phase I study in patients with advanced RCC [58].
CCI-779 was given intravenously once weekly; IFN was
administered subcutaneously three times weekly. The
combination therapy of CCI-779 and IFN appeared to
be generally well tolerated, and partial responses were
observed in seven (13%) of the 55 patients; disease stabi-
lization was documented in 39 patients (71%) including
19 patients for longer than 6 months. A pivotal phase III
study randomizing untreated patients defined as poor risk
by Motzer et al to a combination of CCI-779 and IFN-a,
IFN-a alone, or CCI-779 is underway.
Ongoing and future issues in molecularly
targeted therapies
Although the results of these studies are encourag-
ing, many questions remain. First, few if any patients re-
ceiving these molecularly targeted agents have achieved
a complete response. As studies are very recent, the
durability of partial responses remains to be established
for most of these agents. It is unclear whether these
agents have overlapping spectra of activity and therefore
might be subject to cross-resistance. Furthermore, com-
bination studies seem appropriate, but devising rational
approaches to the design of these combination regimens
remains difficult. Potentially promising combination ther-
apies include combinations of bevacizumab with IL-2,
IFN, erlotinib (Tarceva), or sorafenib. Several of these
combinations are currently under investigation. Finally, it
is also unclear to what extent target expression or the doc-
umentation of target suppression can predict response
to specific therapies. Acquisition of tumor tissue likely
will be required to assess the bioactivity of these specific
agents used either alone or in combination. Enrollment of
patients presenting with stage IV disease, like the patient
presented here, who could receive systemic therapy prior
to undergoing cytoreductive nephrectomy, might prove
critical to the productive investigation of these targeted
approaches.
Epilogue
Today’s patient was given the opportunity to enroll in
the phase II trial of sorafenib in patients with renal cancer.
He received therapy and achieved a minor response that
lasted for close to 6 months. He then developed symp-
tomatic disease progression in his spine, which necessi-
tated termination of treatment. Palliative therapy was
necessary, and unfortunately his disease progressed at a
pace that would not allow consideration of other exper-
imental options. He died approximately 24 months after
his initial diagnosis.
QUESTIONS AND ANSWERS
DR. NICOLAOS E. MADIAS (Chairman, Department of
Medicine, Caritas St. Elizabeth’s Medical Center, Boston,
Massachusetts): You briefly mentioned genetic factors as-
sociated with RCC. What is known about their prognos-
tic significance in terms of response to therapy? Also,
are these genetic factors associated with RCC seen in ac-
quired cystic disease of dialysis patients?
DR. ATKINS: It’s remarkable how little we know about
genetic factors in renal cancer. We are now getting in-
formation with carbonic anhydrase (CAIX), a hypoxia-
inducible factor expressed in patients with VHL muta-
tions in their renal tumors. CAIX expression appears to
be associated with response to immunotherapy. In addi-
tion, one would expect that VHL mutations would also be
required for response to VEGF inhibitors and to some of
the other anti-angiogenic agents now being investigated.
In order to sort this out, we just launched a big effort at
our institution to genotype all RCC tissue to identify the
VHL mutant and wild-type tumors and assess how VHL
status predicts response to various therapies.
With regard to acquired kidney cancer in dialysis pa-
tients, these patients usually develop a papillary renal
cancer. As I mentioned, hereditary papillary renal cancer
is associated with mutations in the c-Met oncogene, which
is the receptor for hepatocyte growth factor (HGF).
Mutations in the c-Met oncogene also have been de-
tected in some sporadic cases of papillary renal cancer.
One could postulate that with dialysis or renal insuf-
ficiency, a tremendous proliferative force is applied to
the kidneys and that HGF is a potential mediator. This
proliferative drive eventually might trigger a mutation in
the HGF receptor, c-Met, and lead to cancer. We need to
learn a lot more about this situation. Papillary RCC is a
relatively rare renal cancer, but maybe the dialysis pop-
ulation can be the key to understanding its underlying
biology. Perhaps collecting tumors from these patients
and determining their c-Met mutational status will pro-
vide some insights.
DR. MADIAS: What do we know about the functional
significance of carbonic anhydrase IX in these tumors?
DR. ATKINS: I believe the function of carbonic an-
hydrase is to neutralize the pH surrounding cells when
they’re exposed to hypoxia. Hypoxic conditions lead to
lower pH as well as to increased expression of hypoxia-
inducible factors, including CAIX, on the surface of those
cells. Its expression in necrotic tissue of other cancers is
common. In most cancers, however, CAIX expression is
associated with a poor prognosis. In renal cancer, be-
cause the VHL mutation is part of the pathophysiol-
ogy underlying the cancer, CAIX is expressed even in
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normoxic conditions and, in that setting, it might serve as
a marker for a less mutated, better differentiated form
of clear cell renal cancer. Such cancers might present
antigens that allow the tumor to be more susceptible to
immunotherapy. Clearly, more investigation is needed to
determine why the expression of CAIX is associated with
response to immunotherapy and to identify whether this
expression predicts response to other therapies such as
anti-antigioenic agents.
DR. MADIAS: Is it known whether carbonic anhydrase
II or IV, the forms of the enzyme normally expressed in
the kidney, change their expression in RCC?
DR. ATKINS: I don’t know the answer with certainty,
but I don’t think other forms or CAIX are up-regulated.
DR. JOHN T. HARRINGTON (Dean Emeritus, Tufts Uni-
versity School of Medicine; Division of Nephrology, Tufts-
New England Medical Center, Boston): Mike, you refer
to the toxic effects of IL-2 in a qualitative mode. Perhaps
you tell us more about the degree of hypotension, the
degree of renal insufficiency, and weight gain.
DR. ATKINS: I tend to gloss over the toxicities because
we’re so used to them. High-dose IL-2 therapy does cause
multi-organ toxic effects that include fever as well as flu-
like symptoms that are probably related to the release
of secondary cytokines. In addition, IL-2 causes a capil-
lary leak syndrome that leads to fluid retention, weight
gain, and intravascular volume depletion and probably
is responsible for the renal insufficiency that develops.
This is mostly prerenal in nature. In many patients receiv-
ing high-dose IL-2 treatment, the creatinine level rises as
much as 1 mg/dL/day. In addition, many patients develop
hypotension that requires pressor support. IL-2-related
release of nitric oxide probably is responsible for the hy-
potension. Fortunately, shortly after stopping IL-2 ther-
apy, diuresis ensues, and renal function abnormalities and
hypotension completely resolve.
We’ve tried a number of ways to dissociate toxicity
from the antitumor effects of IL-2. We think that the hy-
potension is mediated via secondary cytokines such as IL-
1 or TNF. We’ve performed studies looking at the effect
of IL-2 toxicity on the co-administration of either solu-
ble receptors to IL-1 or TNF, inhibitors of TNF or IL-1
production or signaling, or inhibitors of nitric oxide pro-
duction. As yet, we have not identified an approach that
can block the toxicity of IL-2 without also blocking its an-
titumor effect. We’re hoping in our study with high-dose
IL-2 and bevacizumab that blocking VEGF will block
some of the hypotensive effects of IL-2. We hope that in
addition to possessing nonoverlapping antitumor activ-
ity, bevacizumab also will reduce the toxicity associated
with IL-2.
DR. HARRINGTON: In the post-transplant immunosup-
pressed patient, one frequently sees squamous cell can-
cers. I have some patients now who close to 30 years after
kidney transplantation need to see a dermatologist quite
often to have squamous cell carcinomas removed. I don’t
believe the incidence of RCC is increased. What accounts
for this differential effect of immunosuppression on the
rate of oncogenesis in different tissues?
DR. ATKINS: That’s a very complicated question, but I
assume there are viruses or toxic effects on the skin that
are responsible for these squamous cell cancers. When
patients receive immunosuppressive therapy, they are un-
able to keep these factors in check. The renal transplant
presumably comes from a healthy individual and, conse-
quently, the allograft might be at less risk for renal cancer
during the recipient’s lifetime. Admittedly, this is all spec-
ulative.
DR. ANDREW S. LEVEY (Division of Nephrology,
Tufts-New England Medical Center, Boston): I’m partic-
ularly interested in the renal cancer that develops in a
dialysis patient. As you know, RCC almost always devel-
ops in the setting of acquired cystic disease. One might
think that the proliferative activity that is responsible for
cyst growth is similar to the proliferative activity related
to the tumor growth. Have any of the molecular pathways
that you’ve described been investigated as the cause for
cyst growth? Particularly, is any of the information that’s
become available regarding polycystic kidney disease rel-
evant to the proliferative activity in acquired cystic kidney
disease or renal cancer?
DR. ATKINS: The best answer I can give is mentioning
the Knudson two-hit hypothesis for cancer development,
in which one sees an initial mutation that allows for in-
creased proliferation or decreased destruction of cells,
and a second mutation that leads to malignant transfor-
mation of a subset of proliferating cells [59]. Maybe the
first hit enables and/or is required for cyst development.
Also, perhaps some stress or damage to these cysts during
dialysis facilitates the second hit and, therefore, cancer
development. I don’t know of any relationship between
the molecular biology of the cyst development in acquired
cystic disease versus hereditary polycystic kidney disease,
but it would be worth looking at. If people are removing
kidneys in these patients, it would be worth collecting
tissue for genotypic analysis.
DR. MADIAS: As I recall, the incidence of RCC is not
increased in polycystic kidney disease, although the tu-
mor is much more frequently bilateral compared to the
disease in the general population. This is a dramatic dif-
ference compared to acquired cystic disease.
DR. ATKINS: Polycystic kidney disease has traditionally
been listed as a risk factor for renal cancer. However, I
think that polycystic kidney disease is a very weak risk
factor because most of the more recent studies haven’t
mentioned it. I don’t know what the difference is between
the cysts in these two diseases. It might have something
to do with the patient’s age when the cysts develop.
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DR. HARRINGTON: What is the role of repeated resec-
tions of small pulmonary metastatic nodules today versus
in the past?
DR. ATKINS: I think there is a role for salvage surgery
in patients who have responded to immunotherapy or
in patients who present with isolated metastatic disease
and have a long interval between primary presentation
and presentation of metastatic disease. I don’t think that
there is any clinical value in resecting metastatic disease
that is present at the time of presentation. The principles
of cancer biology tell us that in that situation more disease
is almost certainly present and that it can reveal itself even
during the surgical recovery period.
DR. HARRINGTON: If a patient is diagnosed with non-
metastatic renal cancer, what is the 5-year survival rate?
DR. ATKINS: Differences in the stage of the cancer gen-
erally determine survival. Smaller tumors are treated with
partial nephrectomy; larger ones usually require full or
radical nephrectomy. The median long-term survival for
both populations is over 90%.
DR. HARRINGTON: How does this compare with 10
years ago?
DR. ATKINS: We’ve gotten better in that now we’re
doing less invasive surgery to remove the primary tumor.
However, since 90% of the people are cured by surgery
alone, we can’t improve much on their outcome by adding
systemic therapy. We can only produce benefit in the 10%
of patients who will relapse, and our therapies are not
good enough to make a measurable difference in such a
small number of patients at risk.
DR. MADIAS: You spoke about factors that confer re-
sponse to therapy. Are there known factors that confer
resistance?
DR. ATKINS: That’s a very good question. We have not
identified any. I will assume that some of the molecules
that are expressed in papillary tumors confer resis-
tance, but this definitely is worth looking at. Perhaps the
nephrology community could provide some new ideas.
DR. MADIAS: What do we know about the mechanism
of hypertension associated with VEGF blockade?
DR. ATKINS: We have some clues. I believe that nitric
oxide synthase is controlled by VEGF. So if VEGF sig-
naling is blocked, endothelial NOS (eNOS) expression
in endothelial cells is blocked, and perhaps that leads to
hypertension.
DR. BERTRAND JABER (Vice-Chairman for Clinical
Affairs, Caritas St. Elizabeth’s Medical Center): I am in-
trigued by the cytokine-inducing potency of RCC. Do we
have a general understanding as to the role of the kidney
in the generation and metabolism of cytokines?
DR. ATKINS: Inflammatory cells infiltrate many kid-
ney tumors and can produce cytokines such as TNF, IL-1
TGF-b , and IL-6. Cytokines can contribute to the para-
neoplastic syndromes and to local and systemic immune
suppression.
DR. JABER: As you know, plasma cytokine levels are
elevated in patients with chronic renal failure who un-
dergo maintenance dialysis, and the challenge for us has
been to decipher whether this alteration is due to de-
creased clearance or to increased generation of these in-
flammatory mediators. If the kidneys play a major role
in cytokine generation, should patients with renal fail-
ure undergo a nephrectomy as a cytokine-reductive ther-
apy? This would be quite an interesting hypothesis and
strategy, as pro-inflammatory cytokines are emerging risk
markers for cardiovascular morbidity, the leading cause
of death in dialysis patients.
DR. ATKINS: This is a very interesting concept. If noth-
ing else, removing the kidney would reduce the risk of
dialysis-related renal cancer.
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